Latest:
Emerging Agents and Future Strategies in Relapsed/Refractory CLL
Panelists discuss the role of non-covalent BTKis in this setting and available supporting data (high level).
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
John F. Seymour, MBBS, PhD
Latest:
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Waldenström Macroglobulinemia: Results From the Phase 1 CaDAnCe-101 Study
Dr. John F. Seymour presents preliminary results from the Phase 1 CaDAnCe-101 study, highlighting the efficacy and safety of the BTK degrader BGB-16673 in relapsed or refractory Waldenström macroglobulinemia, demonstrating high response rates, rapid improvements in cytopenias, and promising activity across diverse mutation profiles.
John Gordan, MD, PhD
Latest:
Dr. Gordan on Molecular Diagnostics in Biliary Tract Cancers
John Gordan, MD, PhD, assistant professor, Division of Hematology/Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses how the adoption of molecular diagnostics has helped further treatment efforts in biliary tract cancers.
John H. Stewart, IV, MD
Latest:
Multidisciplinary Melanoma Program Facilitates Patient Care and Clinical Research
The Malignant Melanoma Program at Wake Forest Baptist Health employs a multidisciplinary approach for the management of patients with all stages of this disease. The goals of the program are centered on unequivocal excellence in all areas of care for patients with malignant melanoma.
John H. Suh, MD
Latest:
The Jury's Still Out on Whole-Brain Radiation Therapy for Brain Metastases
Despite the fervent advocacy of stereotactic radiosurgery alone, the addition of whole-brain radiation therapy clearly improves local control, decreases distant brain failure, minimizes the need for salvage therapies such as surgery, and, most importantly, decreases neurologic death.
John Hays, MD
Latest:
Dr. Hays on Targeting Mutations in Gynecologic Cancers
John Hays, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses how researchers are actively exploring how to target rarer mutations in patients with a variety of gynecologic cancers.
John Heymach, MD, PhD, MD Anderson Cancer Center
Latest:
AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC
Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.